Hours after President Trump said Sunday he had "second thoughts" about escalating the trade war with China, the White House sought to explain his remark because it was...Politicsread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
President Donald Trump said Sunday he was not happy after North Korea launched short-range ballistic missiles over the weekend.Politicsread more
The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Bristol-Myers Squibb shareholders approved the pharmaceutical giant's $74 billion acquisition of cancer drugmaker Celgene in a vote on Friday.
The deal, announced in January, was a hard sell to Bristol shareholders from the start, and the approval concludes a tumultuous period for Bristol, which saw pushback from institutional investors.
The acquisition adds about $32 billion in fresh debt to Bristol's balance sheet while assuming $20 billion in Celgene's debt, the companies said at the time.
More than 70% of eligible shareholders voted for the deal, the company said Friday. Roughly 24% of shareholders voted against the deal, and 1% abstained. Both Bristol and Celgene shares were slightly higher in morning trading.
"We are pleased with the outcome of today's Special Meeting and thank our shareholders for their support for this combination," Bristol's Chairman and CEO Giovanni Caforio said in a statement.
Buying Celgene was seen by Wall Street analysts as giving Bristol more cancer drugs at a time when its immuno-oncology portfolio struggles to keep up with rival Merck's. Bristol's blockbuster Opdivo, which boosts the immune system to attack cancer, has fallen behind its leading competitor, Merck's Keytruda.
Hedge funds Wellington Management and Starboard Value in late February said the deal didn't sit well with them. Wellington — which is Bristol's largest institutional holder — said the deal asked Bristol shareholders to accept too much risk. Starboard cited similar concerns, saying the Celgene deal was "poorly conceived and ill-advised."
Starboard eventually ended its fight against the buyout once Institutional Shareholder Services and Glass Lewis recommended Bristol-Myers shareholders vote in favor of its bid.
For more on investing in health-care innovation, click here to join CNBC at our Healthy Returns Summit in New York City on May 21.
Bristol said Friday the deal, which is expected to close in the third quarter of this year, will create a "premier innovative biopharma company with leading scientific capabilities."
"We look forward to bringing the companies together, which we believe will deliver significant shareholder value," Caforio said.